Source comparison
Melanotan-2 Safety Profile: Peptide Class Comparison
Receptor Selectivity Non-selective MC1R–MC5R agonist Primarily MC1R selective Primarily MC4R selective Melanotan-2's broad receptor binding drives multi-system effects Cardiovascular Effects Severe: hypertension, tachycardia in >60% of acute cases Minimal: rar
This comparison does not assign a generated winner or score.
- Receptor Selectivity
- Non-selective MC1R–MC5R agonist
- Primarily MC1R selective
- Primarily MC4R selective
- Melanotan-2's broad receptor binding drives multi-system effects
- Cardiovascular Effects
- Severe: hypertension, tachycardia in >60% of acute cases
- Minimal: rare BP elevation
- Moderate: transient BP increase, typically <20 mmHg
- Melanotan-2 produces the most pronounced cardiovascular activation
- Documented Acute Toxicity Cases
- 47+ peer-reviewed case reports (2010–2026)
- <5 documented cases
- 12 cases, primarily nausea and flushing
- Melanotan-2 has the highest published toxicity event rate
- FDA Approval Status
- Unapproved, explicitly warned against
- Unapproved
- Approved for hypoactive sexual desire disorder (brand: Vyleesi)
- Only PT-141 has undergone Phase III trials and FDA review
- Primary Research Use
- Melanocyte receptor studies, obesity models
- Photoprotection research in erythropoietic protoporphyria
- Sexual dysfunction research, MC4R pathway studies
- Each peptide serves distinct research pathways; they are not interchangeable
- Risk of Priapism
- 19% in documented toxicity cases
- <1% reported
- Not documented
- Melanotan-2 carries significantly higher priapism risk than analogs
- The comparison clarifies that melanotan-2's unique risk profile stems from its non-selective melanocortin receptor agonism. Melanotan-1 was developed as a safer alternative with greater MC1R selectivity, reducing cardiovascular and sexual side effects while retaining melanogenesis activity. PT-141 (bremelanotide) was specifically designed to exploit MC4R agonism for sexual dysfunction treatment and underwent the rigorous clinical trial process that melanotan-2 never completed. Researchers evaluating melanocortin pathways must select the appropriate peptide based on the receptor subtype and biological outcome of interest. Using melanotan-2 when a selective agonist would suffice introduces unnecessary confounding variables and safety risks.